{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:13:06Z","timestamp":1786993986284,"version":"build-2736575974"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.mayocp.2018.08.009","type":"journal-article","created":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T01:25:35Z","timestamp":1546478735000},"page":"84-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost Efficacy of \u03b1-Galactosidase A Enzyme Screening for Fabry Disease"],"prefix":"10.1016","volume":"94","author":[{"given":"Darrell B.","family":"Newman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Matern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn S.","family":"Peck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Maleszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R.","family":"Ommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocp.2018.08.009_bib1","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2014"},{"issue":"25","key":"10.1016\/j.mayocp.2018.08.009_bib2","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.009_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2018.08.009_bib4","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2018.08.009_bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmedgenet-2017-105080","article-title":"Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995-2017","volume":"55","author":"Doheny","year":"2018","journal-title":"J\u00a0Med Genet"},{"issue":"2","key":"10.1016\/j.mayocp.2018.08.009_bib6","doi-asserted-by":"crossref","first-page":"200.e1","DOI":"10.1016\/j.amjmed.2017.09.010","article-title":"Identification of Fabry disease in a tertiary referral cohort of patients with hypertrophic cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2018.08.009_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17122010","article-title":"The large phenotypic spectrum of Fabry disease requires graduated diagnosis and personalized therapy: a meta-analysis can help to differentiate missense mutations","volume":"17","author":"Citro","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.mayocp.2018.08.009_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.mayocp.2014.01.025","article-title":"Characterization of a phenotype-based genetic test prediction score for unrelated patients with hypertrophic cardiomyopathy","volume":"89","author":"Bos","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.mayocp.2018.08.009_bib9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a nationwide screening for Anderson-Fabry disease among dialysis patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.mayocp.2018.08.009_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"issue":"1-2","key":"10.1016\/j.mayocp.2018.08.009_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618306153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619618306153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T05:57:10Z","timestamp":1546495030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619618306153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0025619618306153"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.009","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost Efficacy of \u03b1-Galactosidase A Enzyme Screening for Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9?2018 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}